Sarvnaz Sadrameli
PharmD, BCOP
Rotations
Cellular Therapy (inpatient)
Education
PharmD: University of Texas at Austin College of Pharmacy
Residency Training
PGY1: University of Illinois at Chicago
PGY2 Oncology: University of Wisconsin Hospitals and Clinics - Madison
Practice Interests
Cellular therapy, conditioning regimen optimization, GVHD prevention and management, health economics and outcomes research
Professional Affiliation
Hematology/Oncology Pharmacy Association (HOPA)
American Society for Transplantation and Cellular Therapy (ASTCT)
Recent Publications
Sadrameli S, Bringgold S, Dow-Hillgartner E. Tolerability Assessment of Tyrosine Kinase Inhibitors in Patients With Solid Tumor Malignancies and Hypoalbuminemia. Ann Pharmacother. https://doi.org/10.1177/10600280241284923
Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs. 2021;81(1):125-56.
Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM. Authors' Reply to Bonnet et al. "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update". Drugs. 2021;81(5):615-7.
Waddell D, Collins J, Sadrameli S. Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy. Transplant Cell Ther. 2025; 31(4):238.e1-238.e12. doi: 10.1016/j.jtct.2025.01.887.
Academic and/or National Presentations
Channeling the Immunofury: Updates in Toxicity of Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy. 10th Annual Updates from ASH; Chicago, IL. Feb 2025.